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ABSTRACT 
Objectives 
To characterize the catabolic response of osteoarthritic (OA) chondrocytes to ligands that activate 
most Toll-like receptors (TLR). 
 
Methods 
Induction of the collagenases, matrix metalloproteinase (MMP)-1 and MMP-13, by TLR ligands 
was assessed in chondrocytes by ELISA and real-time PCR. TLR signalling pathway activation and 
their involvement in collagenase induction was analysed by western blotting and use of pathway 
inhibitors and siRNA. TLR ligand expression was compared in femoral head cartilage of normal 
and OA patients. 
 
Results 
Ligands for TLR6/2 and TLR3 showed the greatest up-regulation of MMP-1 and MMP-13 
respectively, although all TLR ligands up-regulated MMP-1 and MMP-13 to some degree. MMP-
13 induction by TLR3 and TLR6/2 ligands was dependent on Trif and MyD88. The induction of 
both MMP-1 and MMP-13 by TLR1/2, 3 and 6/2 ligands was dependent upon the NF-κB pathway, 
but were differentially inhibited by various MAPK inhibitors, with MMP-13 induction most reliant 
on ERK. In addition, ligands for TLR1/2 and TLR6/2, but not TLR3, induced significant 
collagenolysis in a cartilage resorption assay. Finally, TLR2 was significantly down-regulated and 
TLR3 up-regulated in OA, compared to normal, cartilage. 
 
Conclusions 
Activation of chondrocyte TLRs leads to differential collagenase gene activation. Treatment of 
chondrocytes with ligands for TLR1/2 and TLR6/2 resulted in collagen resorption. The modulated 
expression of chondrocyte TLR2 and TLR3 in OA cartilage, compared to normal, may reflect a 
response to repair cartilage or prevent further ECM destruction. These data suggest modulation of 
TLR-mediated signalling as a potential therapeutic strategy for the treatment of OA. 
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INTRODUCTION 
Rheumatoid arthritis (RA) and osteoarthritis (OA) are complex diseases which are still relatively 
poorly understood. Multiple genetic and/or environmental factors are thought to interact to trigger 
disease onset, and although progress has been made in the identification of genetic risk factors [1, 
2], the environmental factors are less well characterised. Despite significant improvements in RA 
treatments following the development of therapeutic anti-cytokine antibodies [3], these do not 
always prevent cartilage and bone destruction, the overriding debilitating factor. 
  
Chondrocytes are the only cartilage cell-type, precisely arranging the extracellular matrix (ECM) 
macromolecules to underpin normal tissue function and architecture [4], and are active players in 
both destructive [5] and reparative processes [6] during disease with pathological destruction 
resulting from homeostatic disruption via dysregulated proteolysis.  
 
Collagenases are unique enzymes that can all specifically cleave fibrillar collagens. They are matrix 
metalloproteinases (MMPs) [7], and increases in collagenase-specific collagenolysis occur in 
pathological cartilage destruction [8] resulting in essentially irreversible loss of tissue integrity [9]. 
MMP activity is regulated at several levels including gene transcription, proenzyme activation, and 
active enzyme inhibition by tissue inhibitors of metalloproteinases (TIMPs) [5]. MMPs are induced 
by tumour necrosis factor α (TNFα) and interleukin-1 (IL-1) and, in combination with the IL-6-
family cytokine oncostatin M (OSM), these pro-inflammatory cytokines synergistically enhance 
MMP production in vitro, ex vivo and in vivo [10-12].  
 
The recently discovered Toll-like receptor (TLR) family has increased awareness of the pivotal role 
innate immune signalling has in immunity to infection (reviewed in [13, 14]). Recognition of a 
diverse array of microbial ligands via TLRs and other innate recognition receptors is now known to 
be crucial in orchestrating appropriate effector mechanisms to combat pathogens [15]. It is also 
clear these same recognition events can be triggered by endogenous ligands [16], resulting in 
inflammation and autoimmunity [17]. Several major signalling pathways are TLR-activated 
including nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways 
[13]. Although signalling by each TLR has much in common, unique molecules and mechanisms 
provide specificity via different adaptor proteins (e.g. MyD88, Mal, Trif and Tram) that activate 
signalling and mediate differential gene expression profiles.  
 
Synovial injection of TLR2, 3, 4 or 9 ligands induces or exacerbates arthritis in several 
experimental models [18-24]. Furthermore, TLRs are expressed in synovium, and ligands detectable 
in inflamed synovium [25] and recognised by TLR2 (e.g. peptidoglycan) up-regulate MMP-1 
expression in synovial fibroblasts [26]. Although TLRs in synovium have been extensively studied, 
less is known about their function in cartilage. Different TLR profiles have been reported for 
chondrocytes, with only TLR2 consistently found [27-29]. Chondrocyte TLR2 and 4 activation 
induces collagenases and subsequent resorption [29] whilst TLR4-activation also increases IL-1β 
mRNA and decreases aggrecan and type II collagen expression [28].  
 
We have assessed a spectrum of TLR ligands to show chondrocytes induce collagenase expression 
following activation of multiple TLRs. Furthermore, ligands for TLR1/2 and TLR6/2, but not 
TLR3, induced cartilage resorption and synergised with OSM. We also found TLR2 and TLR3 are 
significantly down- and up-regulated, respectively, in end-stage OA cartilage which may reflect an 
attempt by chondrocytes to repair cartilage or prevent further ECM destruction. 
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MATERIALS & METHODS 
 
Reagents 
Recombinant human IL-1α was a kind gift form GlaxoSmithKline (Stevenage, UK). Recombinant 
human OSM was from R&D Systems (Minneapolis, USA). TLR ligand Set I was from Apotech 
(Geneva, Switzerland). Sulfasalazine, SP600125, SB203580 and U0126 were purchased from 
Calbiochem (Nottingham, UK). All primary antibodies were from Cell Signaling Technology 
(Danvers, USA), and the polyclonal secondary immunoglobubins/HRP were from Cytomation 
(Dako Denmark). Oligonucleotides and PCR Mastermix were purchased from Sigma-Genosys 
(Poole, Dorset, UK), whilst TaqMan primer/probes were from Applied Biosystems (Foster City, 
CA, USA). Sybr green Mastermix was from Takara (Cambrex, Wokingham, UK). SmartPoolTM 
siRNAs  (Trif: M-012833-00; MyD88: M-004769-00) and siControl were from Dharmacon (Perbio, 
Cramlington, UK). 
 
RNA extraction from cartilage samples and chondrocytes 
Human articular cartilage was obtained from patients undergoing total joint replacement surgery.  
Hip cartilage samples from OA patients were compared to cartilage from fracture to the neck of 
femur (NOF) patients with no known history of joint disease essentially as described [30]; NOF 
cartilages were lesion-free. Intact femoral heads were processed and RNA extracted using 
established methodology [31].  
 
Human articular chondrocytes (HACs) were isolated from OA knee joints by sequential digestion 
and cultured as described [32]. When cells reached 80-90% confluence, the medium was removed 
and replaced with serum-free medium and the next day stimulated with test cytokines and/or TLR 
ligands at the indicated concentrations (Table 1). Total RNA was isolated using the Cells-to-cDNA 
II kit (Ambion (Europe) Ltd., Huntington, UK). HACs were pre-treated with selective pathway 
inhibitors for 30 minutes prior to stimulation. Total cell lysates were prepared using a modified 
Schindler’s buffer and western blotted as previously described [33]. This study was performed with 
Ethical Committee approval from Norfolk and Norwich University Hospital and Newcastle and 
North Tyneside Health Authority and all patients provided informed consent. 
 
Enzyme-linked immunosorbent assay (ELISA) 
MMP-1 and MMP-13 were measured in the conditioned medium samples using standard ELISA 
methods that recognize both the pro- and active form of the relevant MMP as described [34, 35]. 
Samples were assayed in duplicate, and all measurements performed simultaneously. 
 
Real-time RT-PCR 
For TLR expression in cartilage, complementary DNA (cDNA) was synthesized from 0.5 µg of 
total RNA using Superscript II reverse transcriptase and random hexamers according to the 
manufacturer’s instructions (Invitrogen). Oligonucleotide primers and fluorescence-labelled probes 
were as previously described [36], and 18S rRNA primers and probe were from Applied 
Biosystems; all other sequences are listed in Table 2. TaqMan PCR conditions were as described 
[37]. TLR1/2/4/6 expression was determined with a TaqMan Low Density Array (Applied 
Biosystems) and normalized to the level of 18S rRNA gene expression using the calculation 2-∆CT, 
where ∆CT represents CT(target gene) – CT(18S). For standard TaqMan/Sybr Green PCR, mRNA 
levels for each gene were obtained from standard curves, corrected using 18S rRNA levels. Cycling 
conditions with Sybr Green were 95oC 10s, then 40 cycles of 95oC 5s then 60oC 30s and a standard 
dissociation curve analysis. 
 
Gene silencing 
Trif, MyD88 or siControl (non-depleting) siRNAs (100 nM) were transfected into HACs using 
Dharmafect 1 transfection reagent (Dharmacon) following the manufacturer’s protocol. Briefly, 1 x 
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104 cells were seeded into each well of a 96-well plate and transfected with the siRNA the next day. 
Cells were washed 24 hours post-transfection with PBS and cultured in serum-free medium for 
another 24 hours prior to a 24 hour stimulation with the ligands. Total RNA was isolated and 
reverse-transcribed as above. Gene depletion was confirmed by real-time RT-PCR. 
  
Cartilage assays 
Dissected bovine nasal cartilage was cultured in serum-free medium (DMEM containing 25 mM 
HEPES, 2 mM glutamine, 100 µg/ml streptomycin, 100 IU/ml penicillin, 2.5 µg/ml gentamicin, and 
40 U/ml nystatin) overnight as described [11]. Fresh medium, with or without treatments, was 
added (day 0). At day 7, culture supernatants were harvested and medium replaced. Cartilage and 
culture supernatants were again harvested at day 14 and residual cartilage papain-digested. 
Hydroxyproline release was assayed as a measure of collagen degradation [38], and 
glycosaminoglycan release assayed as a measure of proteoglycan degradation [39] and the extent of 
release calculated as a percentage of the total. Collagenase activity in culture supernatants was 
determined by a 3H-acetylated collagen diffuse fibril assay with aminophenylmercuric acetate (0.67 
mM) to activate pro-collagenases [40]. Gelatinolytic activity was assayed by zymography [41]. 
 
Statistical analysis 
Significant differences between patient groups were determined using a 2-sided Mann-Whitney U 
test. Standard TaqMan experiments were performed in at least triplicate for a minimum of three 
separate samples, with data analysed using a 2-tailed student’s t-test. Cartilage experiments were 
performed in quadruplicate for three different cartilages, and significance assessed using ANOVA 
with post-hoc Bonferroni's multiple comparison test using commercial software (SPSS, version 
11.0). 
 
 
RESULTS 
 
TLR2 and TLR3 are differentially expressed between normal and arthritic cartilage 
An initial screen for TLRs (Fig 1) found TLR2 expression in OA cartilage in line with previous 
reports [27-29, 42], but significantly this expression was reduced (p<0.005) compared to normal. 
Conversely, TLR3 expression was significantly increased (p<0.005) in OA cartilage whilst TLR1, 
TLR4 and TLR6 expression levels were essentially unchanged. Generally, TLR2 expression in 
normal cartilage (chondrocytes) was significantly higher than any other TLR analysed, with relative 
expression levels being: TLR2>>TLR4≥TLR6>TLR1>TLR3 (Fig 1). A real-time RT-PCR screen 
of isolated chondrocytes confirmed the expression of most TLRs, although TLR4 expression was 
very low with no detectable TLR8 or TLR9 (data not shown). Of those detected, only TLR1 and 
TLR2 were significantly up-regulated by the pro-catabolic stimulus of IL-1+OSM, whilst TLR7 
was significantly down-regulated; as a control, we could detect TLR gene expression in peripheral 
blood cells (not shown). 
 
TLR ligands selectively and differentially up-regulate collagenase expression in chondrocytes 
Collagenase expression induced by IL-1 or TNFα is thought to be NF-κB-dependent [43], and since 
TLRs also utilize NF-κB, we determined whether TLR activation in HACs could stimulate similar 
expression. Most TLR ligands differentially induced MMP-1 at both mRNA and protein levels 
(Figs 2A and B, respectively); the TLR6/2 ligand, MALP-2, was the most consistent and robust 
stimulus. MMP-13 was also induced by the ligands except CpG (TLR9) (Figs 2A and B), the most 
robust stimulus being poly(I:C) (TLR3). It is important to note the HAC data presented are from 
different patients and although variations between chondrocyte populations were evident as 
previously shown [6], these affects were reproducible. Interestingly, responses for MMP-1 or 
MMP-13 induction by MALP-2 and poly(I:C), respectively were greater than for IL-1+OSM, the 
most potent cytokine combination known to promote human cartilage degradation [11]. Based on 
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these observations, we selected the ligands for TLR1/2, TLR3 and TLR6/2 for further study, and 
demonstrated dose-dependent induction of MMP-1 and MMP-13 gene expression. Most 
significantly, MMP-13 induction following TLR3 activation even at 2 ng/ml poly(I:C) exceeded 
that of IL-1, whilst MALP-2 levels could also be reduced without significantly affecting MMP-1 
induction (Fig 2C). 
 
TLR ligands synergise with OSM to induce collagenase expression 
Similar to the ability of OSM to synergistically induce MMP-1 and MMP-13 expression in HACs 
when combined with IL-1 [6, 44], we found that TLR1/2 and TLR3 ligands also synergised with 
OSM; MMP-1 and MMP-13 levels were significantly higher than IL-1+OSM although no synergy 
was observed with the TLR6/2 ligand (Fig 2D).   
 
TLR1/2 and TLR 6/2 ligands promote cartilage resorption 
TLR2 activation has been shown to induce cartilage resorption [29]. We next examined the ability 
of ligands that act through TLR2, as well as the TLR3 ligand, to resorb cartilage in an established 
model [11]. Proteoglycan (GAG) release comparable to IL-1+OSM was seen for the TLR6/2 ligand 
alone by day 7 and the TLR1/2 ligand by day 14 (Fig 3A and not shown). IL-1+OSM stimulation 
resulted in synergistic, and almost complete, collagenolysis as expected [11]. Alone, both TLR1/2 
and TLR 6/2 ligands promoted modest collagenolysis, whilst inclusion of OSM promoted 
synergistic release (Fig 3B). The TLR3 ligand failed to promote any aggrecan- or collagenolysis, 
even with OSM (Fig 3A and B). The observed TLR1/2 and TLR6/2 ligand-mediated collagenolysis 
correlated with total and active collagenolytic activity levels, most notably when acting 
synergistically with OSM (Fig 3C). Similarly, inclusion of OSM to the TLR1/2 and TLR6/2 ligands 
enhanced detectable levels of active MMP-9 and pro- and active MMP-2 in culture supernatants 
(Fig 3D). The TLR3 ligand failed to modulate gelatinolytic or collagenolytic activities (Figs 3C and 
D). 
 
 
Different signalling pathways control TLR-induced MMP-1 and MMP-13 expression  
TLR1/2, TLR3 and TLR6/2 ligands activated the NF-κB pathway, as determined by IκBα 
degradation, and all three MAPKinase pathways (Fig 4) but not the phosphatidylinositol 3-kinase 
pathway (not shown). However, the activation kinetics differed: the TLR6/2 ligand displayed the 
most rapid activation with complete IκBα degradation and maximal JNK, p38 and ERK 
phosphorylation by 30 min; the TLR1/2 ligand showed a more intermediate activation similar to 
that for IL-1 although the activation was more prolonged; the TLR3 ligand activation was much less 
pronounced than that of the other ligands or IL-1 with only modest degradation of IκBα and MAPK 
phosphorylation by 90 min (Fig 4B). 
 
The induction of both MMP-1 and MMP-13 by the three ligands was sensitive to NF-κB inhibition 
(Fig 5A and B); notably, MMP-13 induction appeared to be more NF-κB-dependent than MMP-1. 
Although the p38MAPK pathway was activated by all the ligands, only MMP-13 induction by the 
TLR1/2 ligand appeared p38-dependent (Fig 5B). Conversely, ERK inhibition significantly reduced 
MMP-13 expression by all the ligands but only modestly reduced TLR1/2-induced MMP-1 
expression. Although MMP-1 expression required JNK for maximal induction (Fig 5A), only 
TLR3-induced MMP-13 was strongly JNK-dependent (Fig 5B).  
 
Gene silencing of MyD88 or Trif resulted in approximately ≥70% depletion of their respective 
transcripts 48 hours post-transfection (Fig 5C). As expected Trif depletion resulted in a significant 
decrease in MMP-1 and MMP-13 induction by a TLR3 ligand which was unaltered by MyD88 
depletion. Similarly, MMP-13 induction by the TLR1/2 and TLR6/2 ligands showed some MyD88-
dependence, which surprisingly also required Trif. Interestingly, MyD88 depletion induced MMP-1 
basal expression but was not required for the TLR ligand induction of MMP-1. 
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DISCUSSION 
 
A major finding of our study was the differential regulation of TLR2 and TLR3 in OA cartilage 
compared to normal. The marked down-regulation of TLR2 in diseased cartilage may represent an 
attempt by chondrocytes to prevent further degradation since TLR2 activation, either alone [29] or 
in combination with TLR1 or TLR6, promotes resorption. Our results show TLR3 activation 
increases MMP-13 expression by chondrocytes, perhaps contributing to the increased MMP-13 
expression observed in OA cartilage (not shown; [37]). We also confirmed the expression of TLR1, 
TLR4 and TLR6 genes although these were not differentially expressed between OA and normal 
cartilage. However, given that TLR1 and TLR6 associate with TLR2, the >10-fold reduction in 
TLR2 expression would significantly alter TLR1/2- and TLR6/2-stimulated effects in disease.  
 
Since TLRs are innate immunity pattern recognition receptors, it is somewhat surprising that we, 
and others, have identified an extensive chondrocyte TLR repertoire [28]. Kim et al. showed TLR2 
and TLR4 ligands, bacterial peptidoglycan and lipopolysaccharide (LPS), could induce MMP-1, 
MMP-3 and MMP-13 in chondrocytes and increase aggrecan- and collagenolysis from cartilage 
[29]. In our experiments peptidoglycan (data not shown) and LPS induced MMP-1 and MMP-13 
expression, but not as robustly as TLR1/2, TLR3 or TLR6/2 ligands. We also failed to induce 
resorption with LPS although this may reflect differences in LPS preparations. TLR2 is up-
regulated in OA lesions [29], and this apparent discrepancy with our data probably reflects different 
methodologies (real-time RT-PCR versus immunohistochemistry) as well as regional gene 
expression differences; we screened RNA from ‘whole’ articular cartilage containing normal and 
diseased areas, suggesting a failure to down-regulate TLR2 expression (as opposed to increased 
expression) may enhance tissue destruction and hence lesions. Furthermore, if a role for TLRs is 
indeed to respond to endogenous ligands [16] resulting from catabolism (see below), this hypothesis 
explains a self-limiting mechanism by which chondrocytes protect against subsequent catabolism, 
preserving the ECM for prolonged periods of time as is prevalent in OA. 
 
TLRs can recognise endogenous ligands [16], for example, TLR2 and TLR4 recognise heat shock 
protein 70 whilst TLR3 is activated by mRNA from necrotic cells [45]. Data suggest monosodium 
urate or calcium pyrophosphate dehydrate microcrystals, found in synovium or articular cartilage 
associated with various arthropathies [27, 46], signal through chondrocyte TLR2 to up-regulate 
MMP expression and drive cartilage destruction [27]. Another large group of relevant endogenous 
ligands are ECM catabolites such as hyaluronan (HA) fragments [47], heparan sulphate [48], and 
fibronectin extra domain A [49]. Recognised by TLR2 or TLR4 [16], these ligands are exposed 
during ECM injury/remodelling; in lung, these TLRs drive inflammation in response to fragmented 
HA whilst protecting against inflammation-associated injury when HA is intact [47]. Similarly, 
high molecular weight HA inhibits MMP expression and angiogenesis [50, 51] whilst IL-1-induced 
hyaluronidase activity mediates HA fragmentation with concomitant loss of joint function [52]; it 
will therefore be interesting to determine the effects of both HA forms on chondrocyte TLR 
activation.  
 
Mouse gene deletion studies suggest reactive arthritis and streptococcal cell-wall fragment-induced 
joint inflammation are TLR4- and TLR2-dependent, respectively (both MyD88-dependent) [18, 
53]. Intra-articular injection of bacterial DNA (or CpG oligonucleotides) can induce a macrophage-
mediated arthritis in mice [21, 22], whilst systemic exposure to TLR ligands (in adjuvant) augments 
arthritis [18-20]. Interestingly, peptidoglycans (recognised by TLR2) are present in RA synovium 
[25] and up-regulate MMP-1 expression in synovial fibroblasts [26], strongly suggesting a role for 
TLRs in RA-associated joint degradation. TLR3 is trans-activated in response to necrotic synovial 
fluid cells [54] and mice injected with dsRNA develop a self-liming arthritis [23, 24]. Our data 
confirm that TLR3 activation can markedly induce the expression of chondrocyte MMP-13, yet 
poly(I:C) added to cartilage, even in the presence of OSM, failed to promote resorption. This could 
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be due to a failure of this ligand to penetrate cartilage or ligand instability over the extended culture 
period. However, the ability of poly(I:C) to suppress synovial proliferation and cytokine production 
via a type I interferon (IFN)-dependent mechanism [55], coupled with our observation that IFNα 
blocks cytokine-induced cartilage resorption (Rowan, unpublished), suggest that TLR3 ligands 
actually prevent resorption which also explains increased TLR3 expression in OA cartilage - a 
‘defence’ mechanism restricting catabolism.  
 
The differential regulation of MMP-1 and MMP-13 by different TLR ligands was marked, 
especially the significant TLR3-dependent induction of MMP-13. Our data showed that MMP-1 
induction by the TLR ligands to be less NF-κB-dependent than for MMP-13, substantiating a 
previous IL-1 study [56]. TLR3 signalling uses the adaptor Trif and consistent with our data is 
considered MyD88-independent [57]. MyD88 depletion reduced MMP-13 induction by TLR1/2 and 
TLR6/2 ligands. However, this depletion consistently resulted in MMP-1 up-regulation, perhaps via 
co-depletion of MyD88s, a splice variant which negatively regulates TLR signalling [58]. MMP-13 
induction by the three selected ligands was critically dependent on ERK, with other MAPK 
pathways showing differential importance (TLR1/2 was p38MAPK-dependent whilst TLR3 
required JNK). Together, these data confirm collagenase induction in chondrocytes depends on 
unique combinations of signalling pathways and cross-talk [43]. Our study demonstrates that 
chondrocytes respond to a wide range of TLR ligands by inducing collagenase gene expression and 
cartilage destruction. Moreover, for the first time we have shown that TLR activation in the 
presence of OSM synergistically induces collagenase gene expression to levels that exceed those 
previously reported for the most potent inducer of human cartilage catabolism [11]. Thus, specific 
TLR-induced collagenase expression can contribute to the cartilage catabolism prevalent in both 
RA and OA, and modulation of chondrocyte TLR expression or activation may represent a 
mechanism to prevent cartilage destruction. Future work will aim to identify novel endogenous 
TLR ligands in synovial fluid of OA and RA patients to determine the extent that TLR activation 
plays in disease progression. 
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FIGURE LEGENDS 
 
Figure 1 Differential TLR gene expression in normal and OA cartilage. The gene expression 
levels of TLR1, 2, 3, 4 and 6 in hip cartilage from OA (shaded bars; n = 12) or normal (fractured 
neck of femur; NOF) (open bars; n = 12) patients were determined as described in Materials and 
Methods and normalized to the level of 18S rRNA. Since all primer/probe combinations amplify 
with essentially equal efficiencies, TLR expression levels are directly comparable. Significant 
differences between the normal and OA groups were determined using a 2-sided Mann-Whitney U 
test where ** p<0.01.  Lines within the boxes represent the median, the boxes represent the 25th 
and 75th percentiles, and the lines outside the boxes correspond to the minimum and maximum 
values. 
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Figure 2 MMP-1 and MMP-13 induction by human chondrocytes following TLR activation. 
(A) Real-time PCR analysis for mRNA expression of MMP-1 and MMP-13 in primary HACs after 
24 hours stimulation with IL-1 or TLR ligands (concentrations shown in Table 1). Results were 
normalized to 18S rRNA and presented graphically as fold induction relative to control. (B) ELISA 
quantification of MMP-1 and MMP-13 protein expression. Conditioned media from A were assayed 
as described in the Materials and Methods. (C) Real-time PCR analysis of MMP-1 and MMP-13 
gene expression in primary HACs in response to different concentrations of TLR1/2, TLR3 or 
TLR6/2 ligands. (D) TLR ligands synergise with OSM to further induce MMP-1 and -13 
expression. HACs were stimulated with TLR ligands ± OSM at the concentrations indicated (Table 
1) for 24 hours and RNA isolated. Gene expression was measured by real-time PCR as described 
above. For all figures, values are expressed as mean of triplicate wells ± SEM. Data presented are 
representative of at least two independent experiments and statistical significance was calculated 
using a simple 2-tailed student’s t-test (treatment compared with control). Significance is 
represented above each bar, where * p<0.05, ** p<0.01. 
 
Figure 3 Effects of TLR ligand activation on cartilage resorption. Bovine nasal cartilage was 
cultured in serum-free medium in the presence of either medium alone, or medium containing 
TLR1/2, TLR3 or TLR6/2 ligands, or IL-1±OSM (concentrations in Table 1) for 14 days. (A) 
Glycosaminoglycan (GAG) release into the medium was assayed using the dimethylmethylene blue 
assay [39] and is shown for day 7 and expressed as a percentage of the total. (B) The levels of 
collagen fragments released into the medium were determined by measurement of hydroxyproline 
[38]. Results shown are for the cumulative collagen release at day 14 of culture and expressed as a 
percentage of the total (mean ± SD). (C)  The levels of pro- and active collagenase activity in the 
media from cultured cartilage at day 14 were measured as described [40]. (D) As a measure of 
gelatinase activity, the day 14 culture media were analysed by gelatin zymography. All assays were 
performed in quadruplicate. Significance was analysed with respect to TLR ligand compared with 
control, or TLR ligand with TLR ligand + OSM, where *p<0.05, **p<0.01, ***p<0.001 as 
described. 
 
Figure 4 Signalling pathway activation in response to TLR ligand stimulation of human 
chondrocytes. (A) Protein was isolated from HACs at selected time points following TLR or 
cytokine stimulation as indicated.  IκBα degradation (NF-κB pathway) and MAPK activation were 
analysed by 10% SDS-PAGE western blotting using specific antibodies as described. The anti-pan-
ERK and anti-GAPDH antibodies act as loading controls.  (B) Quantitation of western blots was 
performed using ImageMaster 1D software (GE Heathcare) and plotted as pixel density after 
background subtraction. Data presented are representative of at least two independent experiments. 
 
Figure 5 Signalling pathways in collagenase gene induction by selective TLR ligands. HACs 
were pre-treated with the NF-κB pathway inhibitor sulfasalazine (625 µM), p38 inhibitor SB203580 
(10 µM), ERK (MEK1/2) inhibitor U0126 (10 µM) or JNK inhibitor SP600125 (30 µM) for 30 min 
before stimulation with various TLR ligands (Table 1). RNA was isolated 24 hours post-stimulation 
and (A) MMP-1 or (B) MMP-13 gene expression measured by real-time RT-PCR. (C) Primary 
HACs were transfected with siRNA to MyD88 or Trif, and MMP-1 and -13 gene expression 
measured by real-time RT-PCR following 24 hours of TLR ligand stimulation.
 
In all figures, results 
were normalized to 18S rRNA and presented graphically as relative mRNA levels compared with 
vehicle control (0.1% DMSO). Values are expressed as mean of quadruplicate wells ± SEM. All 
data presented are representative of at least two independent experiments and statistical significance 
was calculated using a simple 2-tailed student’s t-test (treatment compared with control). 
Significance is represented above each bar, where * p<0.05, ** p<0.01, *** p<0.001.
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Table 1. Concentration of TLR ligands and cytokines used in experiments 
Toll-Like Receptors Ligands Concentration 
TLR1/2 Pam3CSK4.3HCL 100ng/ml 
TLR3 Poly(I:C). potassium salt 100µg/ml 
TLR4 LPS from E. coli R515 1µg/ml 
TLR5 Flagellin (purified) 100ng/ml 
TLR6/2 MALP-2 100ng/ml 
TLR7/8 Poly (U). potassium salt 10µg/ml 
TLR9 CpG ODN 2395 10µg/ml 
Cytokines   Concentration 
IL-1α  0.02ng/ml 
OSM  10ng/ml 
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Table 2. PCR primers or assays used 
Gene Primer 
MMP-1 F 5’-AAGATGAAAGGTGGACCAACAATT-3’ 
R 5’-CCAAGAGAATGGCCGAGTTC-3’ 
Probe 5’-FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA-3’ 
 
MMP-13 F 5’-AAATTATGGAGGAGATGCCCATT-3’ 
R 5’-TCCTTGGAGTGGTCAAGACCTAA-3’ 
Probe 5’-FAM-CTACAACTTGTTTCTTGTTGCTGCGCATGA-TAMRA-3’ 
 
18S F 5’-CGAATGGCTCATTAAATCAGTTATGG-3’ 
R 5’-TATTAGCTCTAGAATTACCACAGTTATCC-3’ 
Probe 5’-FAM-TCCTTTGGTCGCTCGCTCCTCTCCC-TAMRA-3’ 
 
MyD88 F 5’-CTTTTGGCAATCCTCCTCAA-3’ 
R 5’-CTGCTCGAGCTGCTTACCA-3’ 
 
Trif F 5’-CTCACCTGACCCCCTCCT-3’ 
R 5’-AATTTCTGTTCCGATGATGATTC-3’ 
 
TLR3 F 5’-AGTTGTCATCGAATCAAATTAAAGAG-3’ 
R 5’-AATCTTCCAATTGCGTGAAAA-3’ 
 
TLR1 Applied Biosystems: Assay Number: Hs00413978_m1 
TLR2 Applied Biosystems: Assay Number: Hs00152932_m1 
TLR4 Applied Biosystems: Assay Number: Hs00152939_m1 
TLR6 Applied Biosystems: Assay Number: Hs00271977_s1 
18S Applied Biosystems: Assay Number: Hs99999901_s1 
 





